Combination drug therapy for advanced gynecologic cancers with a specific genetic marker
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests two drugs together for advanced ovarian, endometrial, or cervical cancer that has a specific genetic feature called MSI-H or dMMR. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced ovarian, endometrial, or cervical cancer that has come back or spread.
- Your tumor has a specific genetic marker called MSI-H or dMMR (your doctor can test for this).
- You have already had at least one type of cancer treatment for your advanced disease.
- You are generally able to care for yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, sacituzumab tirumotecan and tagitanlimab, for people with advanced esophageal or stomach cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a combination of two drugs (sacituzumab tirumotecan and tagitanlimab) for people with advanced triple-negative breast cancer that has progressed after earlier treatments. The goal is to see if this combination can help control the cancer.
This trial tests a new drug called Sac-TMT for people with advanced squamous cell carcinoma of the vagina or vulva that has spread or cannot be cured with standard treatments. The drug targets a protein on cancer cells to deliver chemotherapy directly to the tumor, potentially slowing or stopping its growth.
This trial is testing a new drug called Sac-TMT for people with advanced ovarian cancer that has not responded well to initial platinum-based chemotherapy and does not have a specific gene change called HRD. It aims to see if this drug can work better than standard treatment.
This trial tests a new drug, Sac-TMT, given alone or with an immunotherapy drug (pembrolizumab) for people with advanced triple-negative breast cancer who have not yet received any treatment for advanced disease. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new sequence of drugs (Sac-TMT followed by capecitabine) versus capecitabine alone for people with early-stage, high-risk triple-negative breast cancer who do not have BRCA mutations. It aims to see if the added treatment helps prevent the cancer from coming back.
Hear when a new Recurrent or Metastatic MSI-H/dMMR Gynecological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.